Jonathan Wesley Riess, M.D., M.S.
Dr. Jonathan Wesley Riess is a thoracic oncologist at the UC Davis Health Medical Center. As Medical Director of Thoracic Oncology, he relies on advances in diagnostics, targeted therapies, and immunotherapy in the care of patients with malignant mesothelioma, lung cancer, and other thoracic cancers. In addition to his clinical care, he is also actively involved in research aimed at improving the lives of people with cancer and has won numerous prestigious awards in recognition of his contributions. He is board-certified in Oncology, Internal Medicine, and Hematology.
Education and Career
Dr. Riess graduated from Swarthmore College with a degree in Psychobiology, and then completed his medical degree at the Robert Wood Johnson Medical School in Camden, New Jersey. He completed his internship and residency in Internal Medicine at UC San Francisco and a fellowship in Hematology/Oncology at the Stanford University School of Medicine, where he also earned a Master of Science degree in Epidemiology and Clinical Research.[2]
Since completing his education, he has served as a professor at the University of California Davis Comprehensive Cancer Center, focusing on personalized cancer care through targeted treatments and immunotherapy and focused on research and treatment of thoracic cancers, including malignant mesothelioma and lung cancer. In 2021 he was named the new medical director of the cancer center’s Thoracic Oncology Program. He serves on the Non-Small Cell Lung Cancer/Malignant Pleural Mesothelioma/Thymomas and Thymic Carcinomas Panel for the National Comprehensive Cancer Network (NCCN).[1]
Research Interests and Honors
Dr. Riess’ research interests lie in investigating novel diagnostics, targeted therapies, and immunotherapy in lung cancer and other thoracic malignancies. He is the past recipient of several research-related awards and honors, including the National Cancer Institute (NCI) Cancer Clinical Investigator Team Leadership Award and the Addario Lung Cancer Foundation and Van Auken Foundation Young Innovators Team Award. He is the recent recipient of an NCI R01 grant for an NCI-sponsored clinical trial.[1]
Dr. Riess leverages novel diagnostics, targeted therapies, and immunotherapy to deliver high-quality, innovative, and compassionate care to patients with malignant mesothelioma, lung cancer, and other thoracic cancers.
